These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 26289076)

  • 1. Evaluation of dose reduction versus standard dosing for maintenance of remission in patients with spondyloarthritis and clinical remission with anti-TNF (REDES-TNF): study protocol for a randomized controlled trial.
    Pontes C; Gratacós J; Torres F; Avendaño C; Sanz J; Vallano A; Juanola X; de Miguel E; Sanmartí R; Calvo G
    Trials; 2015 Aug; 16():370. PubMed ID: 26289076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Long-Term Etanercept Treatment on Clinical Outcomes and Objective Signs of Inflammation in Early Nonradiographic Axial Spondyloarthritis: 104-Week Results From a Randomized, Placebo-Controlled Study.
    Dougados M; van der Heijde D; Sieper J; Braun J; Citera G; Lenaerts J; van den Bosch F; Wei JC; Pedersen R; Bonin R; Jones H; Marshall L; Logeart I; Vlahos B; Bukowski JF; Maksymowych WP
    Arthritis Care Res (Hoboken); 2017 Oct; 69(10):1590-1598. PubMed ID: 28482137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis.
    Gratacós J; Pontes C; Juanola X; Sanz J; Torres F; Avendaño C; Vallano A; Calvo G; de Miguel E; Sanmartí R;
    Arthritis Res Ther; 2019 Jan; 21(1):11. PubMed ID: 30621746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Withdrawal of medical therapies in axial spondyloarthritis: what would be the optimal trial design?
    Kiltz U; Baraliakos X; Braun J; van der Heijde D
    Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S47-50. PubMed ID: 24129137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, safety and cost per responder of biologics in the treatment of non-radiographic axial spondyloarthritis.
    Olivieri I; Fanizza C; Gilio M; Ravasio R
    Clin Exp Rheumatol; 2016; 34(5):935-940. PubMed ID: 27385374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.
    Dretzke J; Edlin R; Round J; Connock M; Hulme C; Czeczot J; Fry-Smith A; McCabe C; Meads C
    Health Technol Assess; 2011 Feb; 15(6):1-244. PubMed ID: 21291629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose reduction of biological treatment in patients with axial spondyloarthritis in clinical remission: Are there any differences between patients who relapsed and to those who remained in low disease activity?
    Almirall M; Salman-Monte TC; Lisbona MP; Maymó J
    Rheumatol Int; 2015 Sep; 35(9):1565-8. PubMed ID: 25994091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ChemoPROphyLaxIs with hydroxychloroquine For covId-19 infeCtious disease (PROLIFIC) to prevent covid-19 infection in frontline healthcare workers: A structured summary of a study protocol for a randomised controlled trial.
    McEniery CM; Fisk M; Miles K; Kaloyirou F; Hubsch A; Smith J; Wilkinson IB; Cheriyan J
    Trials; 2020 Jul; 21(1):604. PubMed ID: 32616067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-tailored dose reduction of TNF-α blocking agents in ankylosing spondylitis patients with stable low disease activity in daily clinical practice.
    Arends S; van der Veer E; Kamps FB; Houtman PM; Bos R; Bootsma H; Brouwer E; Spoorenberg A
    Clin Exp Rheumatol; 2015; 33(2):174-80. PubMed ID: 25797228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The adherence to ASAS classification criteria and to ASAS recommendations for the use of anti-TNH-alpha agents in axial spondyloarthritis.
    Spadaro A; Lubrano E; Marchesoni A; Cauli A; Cantini F; Carotti M; D'Angelo S; Grassi W; Lapadula G; Macchioni P; Mathieu A; Punzi L; Ramonda R; Salaffi F; Salvarani C; Scarpa R; Olivieri I
    Clin Exp Rheumatol; 2014; 32(4):465-70. PubMed ID: 24850468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
    Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
    Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Withdrawal of biologic therapy in axial spondyloarthritis: the experience in early disease.
    Song IH; Haibel H; Poddubnyy D; Braun J; Sieper J
    Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S37-42. PubMed ID: 24129135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficiency of dose reduction strategy of etanercept in patients with axial spondyloarthritis.
    Lian F; Zhou J; Wang Y; Chen D; Xu H; Liang L
    Clin Exp Rheumatol; 2018; 36(5):884-890. PubMed ID: 29652659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness of TNF-Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF-Blocker Injections in Rheumatoid Arthritis Trial.
    Vanier A; Mariette X; Tubach F; Fautrel B;
    Value Health; 2017 Apr; 20(4):577-585. PubMed ID: 28407999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Remission in nonradiographic axial spondyloarthritis treated with anti-tumor necrosis factor-α drugs: an Italian multicenter study.
    Lubrano E; Perrotta FM; Marchesoni A; D'Angelo S; Ramonda R; Addimanda O; Olivieri I; Punzi L; Salvarani C
    J Rheumatol; 2015 Feb; 42(2):258-63. PubMed ID: 25512483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial.
    Garcia-Vicuña R; Abad-Santos F; González-Alvaro I; Ramos-Lima F; Sanz JS
    Trials; 2020 Sep; 21(1):772. PubMed ID: 32907638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adalimumab efficacy in enteropathic spondyloarthritis: A 12-mo observational multidisciplinary study.
    Luchetti MM; Benfaremo D; Ciccia F; Bolognini L; Ciferri M; Farinelli A; Rossini M; Mosca P; Triolo G; Gabrielli A
    World J Gastroenterol; 2017 Oct; 23(39):7139-7149. PubMed ID: 29093622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial.
    Caballero Bermejo AF; Ruiz-Antorán B; Fernández Cruz A; Diago Sempere E; Callejas Díaz A; Múñez Rubio E; Avendaño-Solá C; Ramos Martínez A; Sancho López A;
    Trials; 2020 Sep; 21(1):794. PubMed ID: 32938496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Withdrawal of biologic therapy in axial spondyloarthritis: the experience in established disease.
    Baraliakos X; Kiltz U; Heldmann F; Sieper J; Braun J
    Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S43-6. PubMed ID: 24129136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.